innerbuddies gut microbiome testing

Gut Microbiome and Diverticular Disease: What the Research Says

Diverticular disease—ranging from diverticulosis to diverticulitis—has long been viewed through the lens of fiber intake, gut motility, and inflammation. But growing evidence suggests the gut microbiome plays an equally important role in whether the intestinal lining stays calm or tips toward inflammation. In people with diverticular disease, gut bacterial communities often look different from those in healthy controls, hinting that microbial balance may influence disease risk and symptom patterns.

Research indicates that shifts in the composition and metabolic activity of gut bacteria can affect the gut environment in several ways: they may alter how the intestine handles fermentable fibers, change the production of protective short-chain fatty acids (like butyrate), and influence inflammatory signaling. When the microbiome becomes less supportive of the intestinal barrier and more prone to promoting inflammatory byproducts, the colon may be more vulnerable to complications—particularly during flares when diverticula become inflamed.

The good news is that microbiome science is also uncovering practical prevention pathways. Diet patterns that support a diverse microbiome—especially those rich in fiber that feeds beneficial microbes—may help maintain a healthier colonic environment. Alongside fiber, factors such as physical activity, gut motility, and antibiotic exposure may shape microbial resilience over time. In this evidence-based overview, we’ll break down what studies have found about gut bacteria shifts, inflammation, and actionable strategies that may help reduce risk and support long-term gut health.

Test your gut microbiome to support diverticular disease insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Diverticular disease

Diverticular disease spans from incidental diverticulosis to inflammatory diverticulitis, and growing evidence highlights the gut microbiome as a key co-factor in why some people develop symptoms or progress. A resilient, fiber‑fermenting microbiome produces short‑chain fatty acids (notably butyrate) that strengthen the colon’s barrier and support balanced local immune signaling; when dysbiosis occurs, SCFA production can fall and inflammatory tone may rise. Microbial activity also influences bile acid metabolism and mucosal signaling, helping explain the wide variability in symptom presentation and risk of complications. Practically, prevention aligns with current recommendations—higher dietary fiber, regular bowel habits, and strategies to reduce constipation—while researchers continue to explore microbiome‑targeted interventions and signatures that could predict flare risk or guide therapy.

Microbial patterns in diverticular disease often show reduced abundance or activity of beneficial, fiber‑fermenting taxa and increased potential inflammatory bacteria, contributing to lower SCFA output and a less robust mucosal environment. Testing services like InnerBuddies aim to translate these patterns into personalized prevention guidance by clarifying inflammation and bile acid signaling in the gut. Such microbiome insights can inform targeted nutrition (e.g., prebiotic fibers) and lifestyle adjustments to improve transit and barrier resilience, but they complement—not replace—traditional medical evaluation, especially if red‑flag symptoms like fever, worsening tenderness, or bleeding occur.

  • Reduced abundance of butyrate-producing bacteria (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale) lowers butyrate production, weakening the colonic barrier and biasing toward a pro-inflammatory state that can raise diverticulitis risk.
  • Loss of other fiber-degrading taxa (Ruminococcus bromii) diminishes fiber fermentation and SCFA availability, undermining mucosal resilience.
  • Lower levels of beneficial taxa such as Bifidobacterium spp. and Akkermansia muciniphila can impair mucosal defense and contribute to symptom susceptibility.
  • Enrichment of pathobionts and non-fiber-associated Bacteroides (e.g., Escherichia coli, Enterococcus spp., Streptococcus spp., Bacteroides vulgatus group, Ruminococcus gnavus group, Bilophila wadsworthia, Fusobacterium spp., Dialister spp.) associates with higher inflammatory tone and risk of diverticular inflammation.
  • Microbial shifts alter bile acid metabolism, which can modulate mucosal signaling, motility, and inflammatory responses relevant to diverticular disease.
  • Dietary fiber and prebiotic substrates can modulate the microbiome toward SCFA production and barrier support, making fiber intake a practical lever for prevention.
  • Microbiome testing can help personalize prevention by revealing whether an individual’s ecosystem favors barrier protection and anti-inflammatory signaling, guiding targeted nutrition or probiotic strategies alongside standard care.
Test your gut microbiome to support diverticular disease insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Other GI indications often discussed with the microbiome

Diverticular disease refers to a spectrum that begins with diverticulosis (formation of small pouches in the colon) and can progress to diverticulitis (inflammation or infection of those pouches). While age, dietary patterns, and gut motility all influence risk, accumulating evidence points to the gut microbiome as an important co-factor in why diverticular disease appears and sometimes flares. The colon’s microbial ecosystem can affect barrier function, immune signaling, and the inflammatory tone of colonic tissue—factors that may help explain variability in symptoms and progression between people who have diverticula.

Research comparing people with diverticular disease to those without has found differences in microbial composition and metabolic output, particularly involving taxa that influence short-chain fatty acid (SCFA) production, bile acid metabolism, and mucosal immunity. In simplified terms, a “less resilient” or dysregulated microbial community may reduce production of protective metabolites (including SCFAs such as butyrate), weaken the mucosal environment, and promote pathways associated with inflammation. Studies also suggest that gut bacteria can interact with host factors like gut transit time, fiber intake, and constipation—ultimately shaping whether the colon remains in a stable, low-inflammation state or shifts toward susceptibility to inflammatory episodes.

From a practical perspective, microbiome-focused prevention strategies often overlap with what is already recommended for diverticular disease: increasing dietary fiber to support a healthier fermentation environment, maintaining regular bowel habits to reduce pressure and stasis, and limiting dietary patterns that may promote dysbiosis. While probiotic and prebiotic approaches are being actively studied, the most consistent evidence supports lifestyle and diet as foundational “microbiome modulators,” because they reliably influence microbial diversity and functional metabolites. Ongoing research aims to identify microbial signatures that predict risk of diverticulitis, clarify how inflammation and barrier dysfunction interact with dysbiosis, and determine which targeted interventions (e.g., specific fibers, pre/probiotics, or personalized microbiome therapies) may offer the greatest benefit.

  • Lower abdominal pain or cramping (often left-sided)
  • Bloating and increased abdominal gas
  • Changes in bowel habits (diarrhea and/or constipation)
  • Abdominal tenderness
  • Fever (more suggestive of diverticulitis)
  • Nausea or vomiting
  • Blood in the stool (rectal bleeding)
Test your gut microbiome to support diverticular disease insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Diverticular disease

This information is relevant for people who have diverticular disease at any stage—whether they have diverticulosis (diverticula without active inflammation) or have experienced episodes of diverticulitis. It’s especially useful for individuals whose symptoms fluctuate, such as recurring left-lower abdominal cramping, bloating, and changes in bowel habits (constipation and/or diarrhea), because these patterns may reflect ongoing shifts in gut microbial balance rather than a single isolated event.

It may also be particularly relevant if you notice triggers or variability in symptom severity tied to diet, bowel transit time, or bowel irregularity (for example, frequent constipation, straining, or low-fiber eating). Since the gut microbiome can influence protective metabolites like short-chain fatty acids (SCFAs), mucosal barrier function, and inflammation signaling, people trying to understand “why flares happen” may benefit from a microbiome-informed prevention framework that complements standard lifestyle guidance.

Finally, this is relevant for anyone looking to connect symptom patterns to potential warning signs. If abdominal pain is accompanied by fever, increasing tenderness, nausea/vomiting, or rectal bleeding, medical assessment is important to distinguish diverticulitis from other causes. For those with a history of diverticular flares or ongoing gastrointestinal symptoms, a gut microbiome perspective can help guide diet- and lifestyle-focused strategies (e.g., supporting fiber intake and regular bowel function) while researchers continue refining targeted prebiotic/probiotic and microbiome-based approaches.

Diverticular disease (including diverticulosis and episodes of diverticulitis) is common, especially with increasing age. In Western countries, diverticulosis is present in roughly 30–50% of adults by midlife and rises to about 50–70% in older populations (often cited around two-thirds of people over 70). Prevalence varies by geography and diet, with lower rates historically reported in Asia and higher rates in North America and Europe, reflecting environmental/lifestyle factors that also shape gut microbiome composition.

Not everyone with diverticulosis develops diverticulitis. Across population-based estimates, approximately 10–25% of people who have diverticulosis will experience an episode consistent with diverticulitis at some point in their lives, while many remain asymptomatic. Symptoms such as lower abdominal pain or cramping (often left-sided), bloating/gas, and changes in bowel habits (constipation and/or diarrhea) are more frequently reported in people with symptomatic uncomplicated diverticular disease, whereas fever, significant tenderness, and nausea/vomiting are more suggestive of diverticulitis.

Rectal bleeding can occur as well, but its frequency depends on whether a flare is present and how bleeding is defined in studies. Blood in the stool (often described as diverticular bleeding) is a recognized manifestation, sometimes occurring without classic severe inflammatory symptoms. Overall, because diverticular disease ranges from incidental diverticulosis to inflammatory flares, reported prevalence of symptoms varies substantially: epidemiologic studies typically show most burden comes from chronic, milder symptom patterns (pain, bloating, altered stool form) while a smaller fraction—often the minority of those with diverticula—progresses to acute inflammatory episodes.

Test your gut microbiome to support diverticular disease insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Diverticular Disease: What the Research Says

Diverticular disease (from diverticulosis to diverticulitis) has an important connection to the gut microbiome. People with diverticular disease often show differences in the composition of intestinal bacteria and in what they produce—especially metabolites such as short-chain fatty acids (SCFAs). SCFAs (including butyrate) help support the colon’s barrier function and help keep local immune signaling in a balanced, low-inflammation state. When the microbiome becomes dysregulated or less “resilient,” protective metabolite production may drop, potentially making the intestinal lining more vulnerable to irritation and inflammatory flare-ups.

Research also suggests that gut bacteria can influence diverticular disease by shaping bile acid metabolism and mucosal immune responses. Altered microbial activity may affect how the gut environment handles inflammation, and can contribute to a higher inflammatory tone in colonic tissue. This helps explain why symptoms can vary widely between individuals—those with a microbiome that more strongly promotes barrier dysfunction and pro-inflammatory pathways may be more prone to complications such as diverticulitis, while others may remain relatively stable despite having diverticula.

Practically, microbiome-focused prevention aligns closely with established diverticular disease recommendations: increasing dietary fiber, maintaining regular bowel habits to reduce stasis and pressure, and supporting a gut environment less likely to favor dysbiosis. Fiber and prebiotic substrates feed beneficial microbes and promote SCFA production, while constipation and irregular transit can shift microbial ecology in ways that may worsen symptoms like bloating, gas, and cramping. Ongoing studies are evaluating whether specific pre/probiotics or targeted microbiome therapies can help predict or reduce flare risk, particularly when symptoms such as abdominal tenderness, fever (more suggestive of diverticulitis), or rectal bleeding signal escalation beyond uncomplicated diverticulosis.

Test your gut microbiome to support diverticular disease insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Diverticular disease

  • Reduced SCFA (e.g., butyrate) production leading to weaker colonic barrier function and less balanced local immune signaling
  • Microbiome dysbiosis that shifts the balance toward pro-inflammatory pathways, increasing inflammatory tone in colonic mucosa and flare susceptibility
  • Altered bile acid metabolism by gut bacteria, which can change mucosal signaling, gut motility, and inflammation via bile-acid–responsive receptors
  • Changes in mucosal immune modulation (e.g., effects on pattern-recognition signaling and epithelial immune crosstalk), promoting susceptibility to diverticulitis rather than stable diverticulosis
  • Microbial metabolite changes that affect epithelial integrity and repair (beyond SCFAs), increasing vulnerability to irritation from luminal contents
  • Reduced microbiome resilience that makes the ecosystem more sensitive to triggers like constipation and dysregulated transit, promoting symptoms and risk of complications

Diverticular disease is closely tied to the gut microbiome, largely through its effects on the colon’s protective functions. In a healthier, more “resilient” microbial ecosystem, beneficial bacteria ferment fiber to produce short-chain fatty acids (SCFAs) such as butyrate. SCFAs help strengthen the intestinal barrier, nourish colon cells, and support balanced local immune signaling in a low-inflammation state. When dysbiosis occurs, protective SCFA output can drop, making the mucosal lining more vulnerable to irritation and inflammatory flare-ups—potentially shifting the gut from stable diverticulosis toward symptomatic disease and complications like diverticulitis.

Beyond SCFAs, microbiome-driven changes in inflammatory tone can influence diverticular disease risk. Certain microbial communities may promote pro-inflammatory pathways by altering how epithelial cells and immune cells “talk” to each other, including upstream signaling involved in pattern-recognition and epithelial–immune crosstalk. This can increase inflammatory activity in colonic tissue, making the gut environment less able to buffer triggers such as constipation, altered transit, or luminal content irritation. As a result, symptom severity can vary significantly between individuals depending on how strongly their microbiome biases toward barrier-supporting versus inflammation-promoting behavior.

Gut bacteria also affect diverticular disease through bile acid metabolism and other microbial metabolites that shape mucosal responses. Bile acids act as signaling molecules through receptors in the gut lining, influencing motility, epithelial function, and immune activity; when microbial composition changes, bile acid profiles can shift in ways that alter mucosal signaling and inflammation. Collectively, reduced microbiome resilience and metabolite changes (not just SCFAs) can impair epithelial integrity and repair, increasing susceptibility to episodes of worsening symptoms. This framework helps explain why diet and transit patterns that support beneficial microbes (especially through adequate fiber/prebiotics) are often emphasized in diverticular disease prevention.

Test your gut microbiome to support diverticular disease insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In diverticular disease, the intestinal microbiome often shows a shift away from a more “resilient”, barrier-supporting ecosystem. Studies commonly associate symptomatic diverticular disease and diverticulitis-prone states with reduced abundance or activity of fiber-fermenting microbes, leading to lower production of short-chain fatty acids (SCFAs) such as butyrate. Because SCFAs help fuel colonocyte energy, strengthen epithelial tight junctions, and keep local immune signaling in a balanced, low-inflammation state, diminished SCFA output may leave the colonic lining less able to withstand mechanical stress, luminal irritation, and transient inflammatory triggers.

Beyond SCFA patterns, microbiome dysregulation can bias the gut toward a higher inflammatory tone. Altered microbial communities may change epithelial–immune communication through pattern-recognition pathways and other mucosal signaling networks, increasing susceptibility to flare-ups. When dysbiosis reduces the gut’s ability to buffer inflammatory stimuli—often amplified by constipation, irregular transit, or changes in intraluminal conditions—individuals may experience more frequent or more severe symptoms, even when they share similar diverticular anatomy.

Microbes may also contribute by modulating bile acid metabolism and producing additional metabolites that influence mucosal function. Since bile acids act as signaling molecules through receptors in the gut lining, changes in microbial composition can reshape bile acid profiles and thereby affect motility, epithelial integrity, and immune activity. Together, lower barrier-protective metabolite production (including SCFAs) and altered signaling chemistry—such as bile-acid–driven immune modulation—can promote an environment where the colon is more vulnerable to symptomatic diverticular disease and, in susceptible cases, progression toward diverticulitis.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale (incl. butyrate producers)
  • Ruminococcus bromii
  • Bifidobacterium spp.
  • Akkermansia muciniphila
  • Bacteroides uniformis (and other fiber-associated Bacteroides)


Elevated / overrepresented taxa

  • Escherichia coli (pathobionts/enteroadherent strains)
  • Enterococcus spp.
  • Streptococcus spp.
  • Bacteroides spp. (non-fiber-associated, e.g., Bacteroides vulgatus group)
  • Ruminococcus gnavus group
  • Bilophila wadsworthia
  • Fusobacterium spp.
  • Dialister spp.


Functional pathways involved

  • Dietary fiber fermentation and short-chain fatty acid (SCFA; especially butyrate) biosynthesis
  • Butyrate-dependent epithelial barrier maintenance (tight-junction assembly/regulation and mucosal energy metabolism)
  • Bile acid metabolism and secondary bile acid generation (bile acid–receptor signaling shaping inflammation and motility)
  • Microbial modulation of mucosal immune signaling (TLR/NLR and inflammasome-related pathways affecting inflammatory tone)
  • Adherence and virulence-associated pathways of pathobionts/enteroadherent bacteria (e.g., E. coli, Enterococcus, Streptococcus) promoting mucosal irritation
  • Mucus layer and mucin utilization/dynamics (including pathways associated with mucin-degrader activity affecting barrier vulnerability)
  • Protein fermentation and generation of potentially pro-inflammatory metabolites (e.g., branched-chain fatty acids, amines) under reduced fiber conditions
  • Stress and oxidative stress response pathways that can promote persistence of inflammation-prone microbial community states


Diversity note

In diverticular disease, the gut microbiome often shifts toward a less diverse or less functionally “resilient” community, particularly in people with symptomatic diverticular disease or diverticulitis-prone patterns. Research commonly reports changes in the balance of microbes involved in fiber fermentation, with reduced representation or activity of taxa that produce protective short-chain fatty acids (SCFAs) such as butyrate. Because SCFAs support epithelial energy needs, reinforce tight junctions, and help keep local immune signaling appropriately restrained, a drop in these barrier-supporting functions can make the colon more susceptible to irritation and inflammatory flares.

Beyond overall diversity, investigators frequently observe alterations in how the microbial ecosystem processes luminal signals. Dysbiosis may change bacterial capacity to metabolize bile acids—important signaling molecules that influence motility, epithelial integrity, and mucosal immune tone—thereby nudging the gut environment toward a higher inflammatory reactivity. These microbiome-driven changes can also reduce the gut’s ability to buffer transient stressors (like constipation-related stasis), helping explain why symptoms vary widely among individuals who all have diverticula.

Overall, microbiome changes in diverticular disease are less about a single “bad” organism and more about a community-level loss of protective metabolic output and resilience. When diversity and functional balance decline, the ecosystem may generate fewer barrier-friendly metabolites (including SCFAs) and produce an altered signaling milieu that promotes mucosal vulnerability, increasing the likelihood of ongoing symptoms and—depending on susceptibility and clinical context—the transition from uncomplicated diverticular disease toward episodes of diverticulitis.


Test your gut microbiome to support diverticular disease insights Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic “one-size-fits-all” approaches often fail in diverticular disease because symptoms aren’t driven by diverticula alone—they’re strongly influenced by whether the gut microbiome can maintain a resilient, barrier-supporting ecosystem. Many generic diets or supplements don’t reliably increase fiber fermentation in the colon, so short-chain fatty acid (SCFA) production (especially butyrate) may remain low. Without enough SCFAs to support epithelial tight junctions and balanced local immune signaling, the colonic lining can stay more vulnerable to luminal irritation, mechanical stress, and flare triggers, even when people technically “follow the plan.”

    In addition, diverticular disease severity varies widely due to differences in transit patterns, stool consistency, and inflammatory tone, all of which shape the microbiome in real time. If constipation or irregular bowel habits aren’t addressed, microbial communities can shift toward less beneficial functional profiles, making flare risk more likely. Generic symptom control may reduce discomfort temporarily, but it often doesn’t restore microbial stability or buffer inflammatory pathways—so symptoms can recur once triggers persist.

    Finally, many generic solutions overlook microbiome-driven bile acid metabolism and mucosal immune signaling. Altered microbial metabolism can change bile acid profiles that affect gut motility, epithelial integrity, and immune activity. If a solution doesn’t account for these gut-environment “signals” and instead focuses narrowly on broad cleansing, broad-spectrum symptom relief, or non-targeted supplementation, it may not meaningfully change the underlying biology that determines who progresses from uncomplicated diverticulosis to more symptomatic states or diverticulitis-prone patterns.

  • Common mistakes

    • Using one-size-fits-all fiber increases without targeting *effective fermentation* (e.g., choosing poorly tolerated or insufficiently fermentable fibers), so SCFA (especially butyrate) output doesn’t rise enough to support epithelial barrier and balanced immune signaling.
    • Failing to address constipation and irregular transit (stool form, frequency, incomplete emptying), allowing microbiome dysbiosis to persist or worsen despite dietary “plans.”
    • Relying on broad symptom control (e.g., pain/antispasmodic or short-term calming approaches) without restoring the microbial functions that buffer luminal irritation and inflammatory triggers—leading to symptom recurrence.
    • Overlooking bile-acid–microbiome interactions (changing bile acid signaling that affects motility, mucosal integrity, and immune tone), instead focusing only on stool regularity or generic gut soothing.
    • Assuming diverticula alone drive symptoms, rather than stratifying by inflammatory tone and microbial functional deficits (SCFA-producing ecosystem, epithelial resilience).
    • Using indiscriminate probiotics/prebiotics without strain/function fit for diverticular disease patterns, resulting in minimal or inconsistent colonization and no meaningful shift toward barrier-supporting metabolic outputs.
    • Introducing major diet changes too quickly or without tolerance strategy, which can worsen gas/bloating and disrupt adherence—preventing sustained microbiome adaptation.
    • Neglecting personalization based on risk of progression (uncomplicated diverticulosis vs symptomatic diverticular disease vs diverticulitis-prone patterns) and associated gut-environment signals.

What to do

  • General support strategies

    Diverticular disease—from uncomplicated diverticulosis to episodes of diverticulitis—has a meaningful link to the gut microbiome. For many people, the transition from a more balanced microbial ecosystem to dysbiosis can influence what the gut produces, including short-chain fatty acids (SCFAs) like butyrate. SCFAs help nourish the colonic lining, strengthen the barrier function, and support a more regulated, low-inflammatory immune environment in the colon. When protective metabolite production declines, the intestinal wall may become more susceptible to irritation and inflammatory flare-ups, which can help explain why symptoms and complication risk vary widely between individuals.

    A core strategy for microbiome-focused support is creating a dietary pattern that encourages resilient, beneficial microbial activity. Increasing dietary fiber supports regular fermentation by gut microbes, which promotes SCFA production and helps maintain healthier stool form and transit. Alongside fiber, adequate hydration and consistent bowel habits are important, because constipation and prolonged transit can increase gut pressure and alter the microbial environment in ways that may worsen bloating, gas, cramping, and discomfort. Prebiotic fibers—found in foods such as legumes, oats, onions, and garlic—can serve as substrates for beneficial bacteria and may help the microbiome stay more stable over time.

    Because the microbiome also interacts with mucosal immunity and bile acid metabolism, broader “low-inflammatory” gut support can be beneficial. This includes focusing on a diet that emphasizes whole plant foods and minimizes highly processed, low-fiber patterns, while paying attention to individual triggers (for example, certain foods that correlate with symptom flares). Research is ongoing into whether specific probiotic or targeted microbiome therapies can reduce flare risk or improve symptom control, but the most reliable foundation remains the established diverticular disease approach: fiber adequacy, regular bowel function, and early medical evaluation when symptoms suggest escalation (such as fever, worsening abdominal tenderness, or rectal bleeding).

  • Lifestyle recommendations

    • Increase dietary fiber gradually (e.g., fruits, vegetables, legumes, whole grains) and aim for consistent daily intake to support regular stool form and microbiome-friendly SCFA production.
    • Prevent constipation and maintain regular bowel habits (adequate fluids, do not ignore the urge to go, consider fiber supplements if needed) to reduce colonic pressure and stasis.
    • Stay well hydrated throughout the day to help fiber work effectively and support smoother transit.
    • Limit intake of ultra-processed foods and diets low in plant diversity; emphasize a Mediterranean-style pattern that supports a more resilient gut microbiome.
    • If you notice triggers (certain high-FODMAP foods, fatty meals), adjust portion sizes and food choices to reduce bloating/gas/cramping while maintaining overall fiber adequacy.

  • Nutrition recommendations

    • Increase soluble and overall dietary fiber gradually (e.g., oats/bran, psyllium, beans/lentils, fruits/vegetables) to support regular transit, lower constipation, and promote SCFA (notably butyrate) production.
    • Prioritize prebiotic, fiber-rich foods most days (onion, garlic, leeks, asparagus, bananas/plantains, oats, legumes) to feed beneficial gut bacteria and improve microbiome resilience.
    • Aim for a balanced, plant-forward diet with adequate protein and healthy fats (olive oil, nuts, seeds, fatty fish) to support mucosal health and reduce inflammatory signaling.
    • Limit ultra-processed foods and excess added sugars, which are linked with dysbiosis and higher gut inflammation tone; replace with whole-food sources of fiber and micronutrients.
    • Stay well-hydrated, especially when increasing fiber, to help soften stool and reduce colonic pressure that can worsen diverticular symptoms.
    • If you notice food triggers (commonly some people react to certain high-FODMAP foods), personalize fiber type/portions rather than eliminating fiber; consider a structured re-challenge to maintain SCFA support.

  • Supplement considerations

    For diverticular disease, supplement strategies most often focus on improving microbiome function and supporting the colon’s protective environment. Because symptoms and complication risk can relate to how resilient the gut ecosystem is, supplements that increase beneficial microbial activity may help promote production of short-chain fatty acids (SCFAs) such as butyrate. Butyrate supports colon barrier integrity and helps maintain balanced, lower-inflammatory signaling, which may reduce susceptibility to irritation and inflammatory flares. In practice, many people consider prebiotic fibers (e.g., inulin-type fibers or partially hydrolyzed fibers) and targeted probiotic blends, ideally chosen with evidence of tolerance in people who get gas or bloating, since some fermentable substrates can worsen symptoms if introduced too quickly.

    Bile acid and immune modulation are another key rationale behind supplement consideration. Certain probiotic strains and fermentation products may influence bile acid metabolism and mucosal immune tone, potentially shifting the gut environment away from chronic, low-grade inflammation that can amplify diverticular symptoms. Alongside probiotics/prebiotics, some individuals explore adjuncts such as omega-3 fatty acids or other anti-inflammatory nutrients; however, the microbiome remains the central lever. If you use supplements, it’s often helpful to trial one change at a time, monitor stool pattern and abdominal comfort, and adjust based on whether fermentation is well tolerated and whether gas/bloating improves or worsens.

    Finally, timing and symptom context matter. Supplements generally align with standard diverticular disease prevention—particularly maintaining adequate dietary fiber and regular transit—because constipation and slowed motility can increase luminal pressure and shift the microbial balance in unfavorable ways. If symptoms suggest escalation beyond uncomplicated diverticulosis (for example, increasing focal tenderness, fever, or significant rectal bleeding), supplements should not replace medical evaluation, since diverticulitis may require prescription therapy. In ongoing research, more personalized microbiome approaches are being studied to better predict flare risk, but for now, the most reasonable supplement focus is supporting a fiber-rich, microbe-friendly environment while using carefully selected probiotics/prebiotics and watching tolerance over weeks rather than days.

  • Retesting / monitoring note

    For diverticular disease, “retesting” is usually less about repeatedly testing the same single biomarker and more about reassessing risk and symptoms over time—especially when there are changes that could suggest progression from uncomplicated diverticulosis toward diverticulitis. If symptoms worsen (e.g., increasing left-lower abdominal pain, fever, persistent tenderness, or systemic signs), clinical guidelines typically prioritize diagnostic evaluation rather than routine microbiome retesting, since imaging and inflammatory markers can be more immediately informative for ruling in or out diverticulitis.

    If you are using a microbiome-focused approach, retesting is most reasonable when results would change management—such as after implementing fiber and prebiotic strategies, addressing constipation/irregular transit, or completing a targeted course intended to improve microbial resilience. Because the gut microbiome can shift with diet, bowel habits, infections, medications (notably antibiotics and some anti-inflammatories), and even travel, clinicians often consider repeating stool-based assessments only after a consistent baseline routine has been in place (commonly on the order of weeks to a few months), so that changes reflect your regimen rather than short-term fluctuations.

    Finally, retesting may be used for ongoing personalization—particularly if you have recurrent symptoms or a history of flares. In those cases, clinicians may reassess alongside standard follow-up steps (dietary adherence, stool consistency, symptom tracking, and—when indicated—colonoscopy based on age and bleeding history). The goal is to identify whether there’s evidence of improved gut-barrier-supportive metabolite patterns (e.g., higher SCFA-related profiles) and a lower pro-inflammatory signal, while recognizing that no retest can replace standard escalation pathways if red flags for diverticulitis or complications appear.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing can matter in diverticular disease because it may reveal whether your gut ecosystem is supporting or undermining colon health. Individuals with diverticulosis or recurrent symptoms can have meaningful differences in bacterial composition and in the metabolites those microbes produce, particularly short-chain fatty acids (SCFAs) like butyrate. When beneficial SCFA-producing microbes are low or when microbial balance is disrupted, the colon’s barrier function may be less resilient and local immune signaling may shift toward a more inflammatory tone—conditions that can influence whether symptoms stay mild or progress toward flare-ups such as diverticulitis.

    Microbiome data may also help clarify how your gut environment is handling inflammation and bile acid signaling. Gut bacteria can modify bile acids and interact with mucosal immune pathways, which can change how sensitive the lining is to irritation and how readily inflammation is triggered. By understanding your microbial patterns (and sometimes functional signals linked to metabolism), clinicians and patients may better interpret why symptoms vary from person to person, even when the presence of diverticula is similar.

    Finally, microbiome testing can guide more personalized prevention strategies alongside standard recommendations like higher fiber intake, adequate hydration, and regular bowel habits. If testing suggests dysbiosis—such as reduced SCFA-supporting activity or patterns associated with higher inflammatory potential—it may support targeted diet adjustments (prebiotic fibers), lifestyle changes to improve transit, and discussion of whether specific probiotic or other microbiome-focused interventions are worth considering. While testing doesn’t replace medical evaluation for red flags like fever, worsening abdominal tenderness, or bleeding, it can help identify which modifiable factors are most likely to influence your risk and symptom trajectory.

  • How InnerBuddies helps

    InnerBuddies can help in diverticular disease by showing how your gut microbiome is currently supporting (or undermining) colon health. Because this condition has been linked to shifts in bacterial composition and—importantly—in the production of protective metabolites such as short-chain fatty acids (SCFAs) like butyrate, your results can highlight whether your microbiome appears geared toward strengthening the gut barrier and calming local immune signaling, or whether it looks more “dysbiotic,” with reduced barrier-supporting metabolic activity. This can be useful for people who have diverticulosis but frequent symptoms, as it provides a microbiome-centered context for why those symptoms may flare or persist.

    The test may also help you understand inflammation-related patterns in the gut environment, including signals tied to microbial metabolism and pathways that affect how the colon responds to irritation. Research suggests that gut bacteria can influence diverticular disease by shaping bile acid metabolism and interacting with mucosal immune responses—factors that can change the “inflammatory tone” of colonic tissue. By identifying trends in your microbial ecosystem, InnerBuddies can help translate the underlying biology behind symptom variability, even when diverticula are present in more than one person.

    Practically, InnerBuddies can support more personalized prevention strategies alongside the usual recommendations (higher dietary fiber, good hydration, and regular bowel habits). If your results suggest lower SCFA-supporting activity or a pattern associated with higher inflammatory potential, you can use that information to guide targeted nutrition choices (such as prebiotic fibers) and lifestyle adjustments aimed at improving gut resilience and transit. While microbiome testing doesn’t replace medical care—especially if you develop red-flag symptoms like fever, worsening tenderness, or bleeding—it can help you and your clinician identify modifiable drivers that may influence your risk of flare-ups.

Medical Evidence

  • Scientific evidence level

    2 [weak; emerging but inconsistent evidence—mostly association/preclinical with limited causal and intervention data]

  • Clinical relevance note

    Overall confidence (GRADE-inspired): Low to Very low confidence in microbiome-based causality and clinical utility. While dysbiosis patterns have been reported in association with diverticular conditions, heterogeneity, confounding (diet, fiber intake, medication including antibiotics/PPIs/NSAIDs, smoking, obesity, comorbidities), and reverse causality substantially limit interpretation. Methodological inconsistency (16S vs shotgun approaches, batch effects, differences in stool sampling, bioinformatics pipelines, and how controls are selected) further reduces reproducibility and external validity. Across prediction/biomarker efforts, even statistically significant discriminative taxa or diversity metrics have not yet been shown to generalize reliably to independent populations and to outperform standard clinical risk stratification.

    Clinical utility status: As of now, gut microbiome measurement is not validated for routine prevention, diagnosis, or management of diverticular disease/diverticulitis. There is insufficient evidence that microbiome testing improves clinical outcomes (eg, earlier diagnosis, more accurate stratification for outpatient vs inpatient care, better selection of therapies, or improved monitoring). Any current clinical use would be investigational, since the evidence base lacks large, well-powered prospective studies demonstrating that microbiome changes predict incident disease and lacks RCTs where microbiome modulation clearly and reproducibly improves clinically meaningful outcomes (incidence of diverticulitis, complication rates, recurrence reduction) with mechanistic confirmation.

    Key limitations to emphasize: most studies are underpowered and cross-sectional; reverse causality is likely around symptomatic episodes and treatment exposure; stool microbiome may not reflect mucosal microbiota relevant to DD inflammation; and predictive models risk overfitting without rigorous external validation. In short, current data are best viewed as hypothesis-generating for microbiome involvement rather than a basis for clinically actionable testing or targeted therapy.

Title Journal Year Link
The microbiota and diverticular disease: role of dysbiosis and inflammatory pathways Nature Reviews Gastroenterology & Hepatology 2021 View →
Gut microbiota in diverticulitis and the effect of antibiotics: a systematic review and meta-analysis Journal of Clinical Medicine 2020 View →
Microbiome signature of uncomplicated diverticular disease and diverticulitis Gut 2017 View →
Comparison of gut microbiota in patients with diverticulitis and healthy controls Gut Microbes 2016 View →
Altered gut microbiota in patients with symptomatic uncomplicated diverticular disease Gut Microbes 2014 View →

Frequently Asked Questions

    ¿Qué es la enfermedad diverticular y cómo puede progresar?
    La enfermedad diverticular abarca desde la diverticulosis (bolsas en el colon) hasta la diverticulitis (inflamación o infección de esas bolsas). El microbioma intestinal puede influir en el riesgo y en las crisis.
    ¿Cómo se relaciona el microbioma con la diverticular?
    Cambios en la composición bacteriana y en los metabolitos, especialmente los SCFA como el butirato, pueden afectar la barrera intestinal y la inflamación, condicionando los síntomas y el riesgo de crisis.
    ¿Qué son los ácidos grasos de cadena corta (SCFA) y por qué importan?
    Los SCFA se producen cuando las bacterias fermentan la fibra; alimentan las células del colon, fortalecen la barrera y modulan la respuesta inmune local.
    ¿Qué síntomas son comunes?
    Dolor en la parte baja del abdomen (a menudo del lado izquierdo), distensión abdominal, cambios en el hábito intestinal, dolor abdominal; fiebre en diverticulitis, náuseas o vómitos, sangre en las heces.
    ¿Qué tan común es y quién está en riesgo?
    La diverticulosis es común con la edad. En zonas occidentales, aproximadamente 30–50% de adultos modernos y 50–70% de mayores de 70 años. No todos desarrollan diverticulitis.
    ¿Qué factores pueden provocar brotes?
    Estreñimiento, tránsito intestinal irregular y hábitos que favorecen la disbiosis.
    ¿Pueden las pruebas del microbioma ayudar?
    Pueden mostrar qué bacterias están presentes y qué metabolitos se producen, pero no son un diagnóstico y deben interpretarse junto con la información clínica.
    ¿Pueden guiar la prevención o el tratamiento?
    Los resultados pueden ayudar a adaptar la dieta y el estilo de vida (fibra, prebióticos/probióticos), pero no reemplazan la atención médica.
    ¿Qué pasos prácticos para prevenir síntomas?
    Aumentar la ingesta de fibra, mantener la hidratación y la regularidad de las evacuaciones; limitar hábitos que fomenten la disbiosis. Consulte con un profesional sobre probióticos o prebióticos dirigidos.
    ¿Cuál es la diferencia entre diverticulosis y diverticulitis?
    La diverticulosis implica divertículos presentes sin inflamación aguda; la diverticulitis implica divertículos inflamados o infectados y puede requerir tratamiento médico.
    ¿Cuándo debo buscar atención médica urgente?
    Fiebre, dolor abdominal intenso o que empeora, vómitos persistentes, sangre en las heces o dolor súbito intenso.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -